BSECompany Update5d ago · 14 Aug 2026, 11:29 pm
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Dr Reddys Laboratories Ltd · 500124
✦ AI SummaryRegulatory
Dr Reddys Laboratories Ltd has disclosed a GMP inspection by the USFDA at its formulations manufacturing facility in Hyderabad, with four observations issued in a Form 483, which the company will address within the stipulated timeline.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Attachments (1)
📄pdf
Download →
41c10d6f-1f55-4fd6-ad73-4d80be5125e7.pdf
View document text
Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills
Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900
Fax: + 91 40 4900 2999
Email: mail@drreddys.com
Web: www.drreddys.com
August 14, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015
This is to inform you that the United States Food & Drug Administration (USFDA) completed a GMP
inspection at our formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad. The inspection
was conducted from August 6, 2026 to August 14, 2026. We have been issued a Form 483 with four
observations, which we will address within the stipulated timeline.
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR